Please ensure Javascript is enabled for purposes of website accessibility

Foolish Forecast: A Test From BioReference Labs

By Ryan Fuhrmann, CFA – Updated Apr 5, 2017 at 4:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Views you can use to get clues on tomorrow's news.

Lab-testing firm BioReference Labs (NASDAQ:BRLI) continues to be an interesting regional play on an industry that should benefit as medicine becomes more personalized, versus the current one-size-fits-all approach.  Aging baby boomers also mean more medical care as time goes on, suggesting growth in lab tests to diagnose, treat, and prevent medical conditions. Below are the vital stats to get Fools up to speed on the firm's third-quarter earnings announcement, set for tomorrow.  

What analysts say:

  • Buy, sell, or waffle? Three analysts follow BioReference Labs; one is bullish, while two are on the fence with hold ratings. The Motley Fool CAPS community gives the company a favorable five-star rating (out of five).
  • Revenue. Analysts are projecting $60.8 million in third-quarter sales, or about 24% above last year's sales amount. 
  • Earnings. Analysts expect earnings of $0.28, or a penny above last year's $0.27, in quarterly earnings.

What management says:
Back when BioReference Labs reported second-quarter results, management said it would be difficult to grow as fast as the company has historically, but estimated full-year projections would "approach" 20% sales growth and operating income expansion "should exceed 30%."  

What management does:
BioReference Labs is a fraction of the size of archrivals Quest Diagnostics (NYSE:DGX) and LabCorp of America (NYSE:LH), but has proven more than able to compete in the hotly-contested Northeastern lab-testing market, as sales have grown close to 20% annually over the past five years and earnings growth has averaged close to 40% over this time.    

Margins

1/06

4/06

7/06

10/06

1/07

4/07

Gross

50.9%

51.2%

51.2%

52.0%

52.2%

52.1%

Operating

7.6%

8.4%

8.5%

9.3%

9.6%

9.6%

Net

4.6%

5.2%

5.6%

5.8%

5.9%

5.7%

All data courtesy of Capital IQ, a division of Standard & Poor's. Data reflects trailing-12-month performance for the quarters ended in the named months.

One Fool says:
Scale matters in the industry, which benefits Quest and LabCorp because they can achieve economies of scale by spreading more volume over a fixed facility base. Also, a national platform helps them win large contracts with managed-care giants such as UnitedHealth (NYSE:UNH), Aetna (NYSE:AET), and Cigna (NYSE:CI).

What BioReference Labs lacks in clout, it can make up for investors by growing faster. A smaller installed base means that new physician and other contracts have a more significant effect on the top and bottom lines. Plus, it has yet to significantly move outside of the New York metropolitan area, and management recently said it intends to expand "focused testing markets throughout the country."

For more related Foolishness:

LabCorp and UnitedHealth are Stock Advisor selections. Quest Diagnostics and UnitedHealth are Inside Value recommendations.

Fool contributor Ryan Fuhrmann is long shares of Quest but has no financial interest in any other company mentioned. Feel free to email him with feedback or to discuss any companies mentioned further. The Fool has an ironclad disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bio-Reference Laboratories Inc. Stock Quote
Bio-Reference Laboratories Inc.
BRLI.DL
Aetna Inc. Stock Quote
Aetna Inc.
AET
UnitedHealth Group Incorporated Stock Quote
UnitedHealth Group Incorporated
UNH
$513.61 (-0.74%) $-3.85
Cigna Corporation Stock Quote
Cigna Corporation
CI
Quest Diagnostics Incorporated Stock Quote
Quest Diagnostics Incorporated
DGX
$122.35 (-0.40%) $0.49
Laboratory Corporation of America Holdings Stock Quote
Laboratory Corporation of America Holdings
LH
$211.66 (-0.64%) $-1.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.